Drug Trial Radar · NCT07172867
A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
Last checked: Nov 19, 2026Latest source record: Feb 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jan 6, 2026
Primary completion
Jan 23, 2026
Study completion Jan 23, 2026
Sponsor
- Lead sponsor
- Halia Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.
Conditions
- Diabetes Mellitus, Type 2
- Obesity
Interventions
HT-6184Drug
2mg QD
HT-6184 Matching PlaceboDrug
2mg QD
Semaglutide 1 mgDrug
Semaglutide 1 mg, every week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess glycemic control using HbA1c (%)Time frame: From first dose through End of Study (up to 12 weeks per participant)
- Assess weight loss using body weight measurementsTime frame: From first dose through End of Study (up to 12 weeks per participant)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cleveland Clinic Abu Dhabi
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.